A Case of a Patient with a Triple Negative Breast Cancer and Complete Response of Lung, Mediastinal and Skeletal Metastases after Treatment with Paclitaxel and Bevacizumab
Authors:
Z. Bravencová
Authors‘ workplace:
Klinika onkologická, FN Ostrava
Published in:
Klin Onkol 2010; 23(5): 358-360
Category:
Case Reports
Overview
Backgrounds:
Metastatic breast cancer is a disease which is not curable. Thus, prolongation of survival with preserved or improved quality of life is the aim of the treatment. Three phase III studies (E2100, AVADO and RIBBON-1) showed the benefit of adding bevacizumab to the standard 1st line chemotherapy. Higher response rate and longer progression-free survival were achieved in these studies. Bevacizumab does not increase toxicity of the chemotherapy regimens. Since 2007 bevacizumab has been registered for the treatment of patients with metastatic breast cancer.
Observation:
Here we present the case of a patient in which bevacizumab treatment led to excellent results. Lobular breast cancer, pT2N0M0, ER-negative, PR-negative, HER2-negative was diagnosed in a 40-year-old woman in 2003. FAC adjuvant chemotherapy was used. Six years later, in March 2009, a relapse in mediastinal lymphatic nodes, the lungs, pleura and bones was detected. A weekly regimen of paclitaxel in combination with bevacizumab started in May 2009. Paclitaxel treatment finished in November 2009, bevacizumab continued for 11 months till April 2010, when complete remission in the lungs, mediastinum and bones was confirmed. Now only bisphosphonate is being continued.
Conclusion:
our experience also confirms the contribution of bevacizumab in the treatment of metastatic breast cancer.
Key words:
metastatic breast cancer – paclitaxel – bevacizumab
Sources
1. Gray R, Bhattacharya S, Bowden C et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol 2009; 27(30): 4966– 4972.
2. Miles DW, Chan A, Dirix LY et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first‑line treatment of human epidermal growth factor receptor 2- negative metastatic breast cancer. J Clin Oncol 2010; 28(20): 3239– 3247.
3. O’Shaughnessy J, Dieras V, Glaspy J et al. Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2- Negative Metastatic Breast Cancer (MBC). Cancer Res 2009; 69 (Suppl): 512s (Abstract 207).
4. Souhrn údajů o přípravku Avastin. www.sukl.cz
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2010 Issue 5
Most read in this issue
- Diagnostic Pitfalls of HIV‑ Associated Kaposi Sarcoma
- Hand‑ Foot Syndrome after Administration of Tyrosinkinase Inhibitors
- Mucoepidermoid Carcinoma of a Nasal Cavity – a Rare Tumour
- Detection of DNA Hypermethylation as a Potential Biomarker for Prostate Cancer